Prostate Cancer from a Nuclear Oncology Perspective - A Personal Journey

This book provides a comprehensive review of innovative diagnostic methods for prostate cancer, with a particular emphasis on the development of PET radiopharmaceuticals. The author has had the privilege to introduce several tracers into clinical routine practice, including Na¹⁸F, ¹⁸F-FCH, ¹⁸F-FACBC, ⁶⁸Ga-PSMA11, ¹⁸F-PSMA-1007, and ¹⁸F-DCFPyL. Thus, indications in various prostate cancer subgroups are discussed in detail, weighing the pros and cons in clinical practice. In the authors´ practice radiation therapy has been more important and surgical applications; therefore, PET based dose planning is presented in detail. Furthermore, the author has closely followed the development of radiopharmaceutical treatments, particularly in the context of bone pain palliation using radiopharmaceuticals, such as ⁸⁹SrCl₂, ¹⁸⁶ReHEDP, ¹⁵³SmEDTMP, ^117mSnDTPA, and ²²³RaCl₂, and targeted treatments (¹⁷⁷Lu-PSMSA-617, ¹⁷⁷Lu-PSMA-I&T and ²²⁵Ac-PSMA).
Thanks to his experience, the author facilitated the set-up of targeted treatments in various countries: Baltic and Nordic countries, elsewhere in Europe, North America (Canada), and Africa (e.g. Ghana). The author's involvement in promoting therapy tourism to Finland further highlights his breadth of knowledge and practical experience.
This book offers valuable insights into the evolving landscape of diagnostic methods and radiopharmaceutical treatments for prostate cancer. With the author's extensive experience and contributions to the field, readers can gain a comprehensive understanding of these advancements and their implications in clinical practice.

Table des matières

1. Introduction prostate cancer from the point of view of the author and the history of imaging.- 2. Integrated summary of research on radioiodinated estramustine phosphate and estramustine binding protein antibody in prostate cancer treatment.- 3. Summary of Diagnostic Accuracy of 18F-Fluorocholine PET/CT in Prostate Cancer Staging.- 4. Overview of 18F-NaF PET/CT Imaging.- 5. 18F-Fluciclovine (18F-FACBC) Positron Emission Tomography in Prostate Cancer.- 6. PSMA-PET in prostate cancer.- 7. 18F-FLT PET/CT in Prostate Adenocarcinoma .- 8. 18F-FDHT-PET Imaging in the Management of Hormone-Dependent  Prostate Cancer.- 9. Immunoscintigraphy and radioimmunotherapy of prostate cancer incuding own personal journey -anti-PAP and anti-PSMA antibodies.- 10. Briefly about radiation therapy.- 11. PET/CT for Radiation Therapy Planning of Prostate Cancer .- 12. Brief overview of prostate cancer treatment modalities.- 13. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer.- 14. Lu-177-PSMA treatment in prostate cancer.- 15. Clinical Experience in 225Ac-PSMA.- 16. Multicenter trials prostate radioligand therapy (PRLT) in castration resistant cancer.- 17. Meta-analyses and systematic reviews (own experience) in prostate cancer.- 18. Own history of cancer suspicions.- 19. Public appearance because of nuclear oncology (pictorial essay).- . Appendix - ISUP and PI-RADS classifications.

A propos de l'auteur

Prof Kairemo graduated with a MSc (Eng) degree from Helsinki University of Technology (Chemical Engineering) in 1980 before undertaking medical training (MD (86), PhD (93)) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry (94), Nuclear Medicine (96), Health Care Administration (02) and Pharmaceutical Medicine (06) at Helsinki University Central Hospital. He had a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center in 1989-93 in New York. Besides homeland Finland he is licensed medical specialist in Norway (1998), Sweden (2001) and Estonia (2010).
Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). In 2009-2018, he has been the Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center, in Helsinki. Since 2015 he has acted as Visiting Professor in the Nuclear Medicine Department of The University of Texas MD Anderson Cancer Center, in Houston, TX; last visits in 2019, 2022 and 2023.
Prof Kairemo has also held posts in industry, as Medical Director of CTT Cancer Targeting Technologies Oy (2001-6), Medical Director of Imanext Oy (2006-8) and Clinical Director at Advanced Accelerator Applications SA in 2009 (now Novartis Co.).
Besides a few patents prof Kairemo has published more than 250 original publications in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy in 2012 and was President of the 7^th International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland. In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop “Cell Labelling and Cell Therapies” in Helsinki. He also organized the 14^th International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki. He was elected in 2022 as the new President of the WARMTH for 2024-2025.

Résumé

Provisional text
This book provides a comprehensive review of innovative diagnostic methods for prostate cancer, with a particular emphasis on the development of PET radiopharmaceuticals. The author has had the privilege to introduce several tracers into clinical routine practice, including Na¹⁸F, ¹⁸F-FCH, ¹⁸F-FACBC, ⁶⁸Ga-PSMA11, ¹⁸F-PSMA-1007, and ¹⁸F-DCFPyL. Thus, indications in various prostate cancer subgroups are discussed in detail, weighing the pros and cons in clinical practice. In the authors´ practice radiation therapy has been more important and surgical applications; therefore, PET based dose planning is presented in detail. Furthermore, the author has closely followed the development of radiopharmaceutical treatments, particularly in the context of bone pain palliation using radiopharmaceuticals, such as ⁸⁹SrCl₂, ¹⁸⁶ReHEDP, ¹⁵³SmEDTMP, ^117mSnDTPA, and ²²³RaCl₂, and targeted treatments (¹⁷⁷Lu-PSMSA-617, ¹⁷⁷Lu-PSMA-I&T and ²²⁵Ac-PSMA).
Thanks to his experience, the author facilitated the set-up of targeted treatments in various countries: Baltic and Nordic countries, elsewhere in Europe, North America (Canada), and Africa (e.g. Ghana). The author's involvement in promoting therapy tourism to Finland further highlights his breadth of knowledge and practical experience.
This book offers valuable insights into the evolving landscape of diagnostic methods and radiopharmaceutical treatments for prostate cancer. With the author's extensive experience and contributions to the field, readers can gain a comprehensive understanding of these advancements and their implications in clinical practice.

Détails du produit

• Auteurs: Kalevi Kairemo
• Edition: Springer, Berlin
• Langues: Anglais
• Format d'édition: Livre Relié
• Sortie: 10.09.2025
• EAN: 9783031903366
• ISBN: 978-3-0-3190336-6
• Pages: 233
• Illustrations: XV, 233 p. 92 illus., 74 illus. in color.
• Catégories: Sciences naturelles, médecine, informatique, technique > Médecine > Spécialités cliniques; Onkologie, pet, Urologie, Medizin des Harn- und Geschlechtsapparats, Medizinische Bildverarbeitung: Radiologie, PSA, Oncology, nuclear medicine, Urology, Radiation Oncology, prostate cancer, Na18F, external beam radiotherapy